Nilsine Partners LLC Invests $700,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Nilsine Partners LLC bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 33,519 shares of the biopharmaceutical company's stock, valued at approximately $700,000.

Other large investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 681 shares during the period. nVerses Capital LLC acquired a new position in shares of Catalyst Pharmaceuticals in the third quarter worth $50,000. Larson Financial Group LLC increased its position in shares of Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 2,994 shares during the period. KBC Group NV raised its stake in shares of Catalyst Pharmaceuticals by 48.8% in the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock valued at $98,000 after acquiring an additional 1,542 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new position in Catalyst Pharmaceuticals in the fourth quarter valued at $134,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Price Performance

Shares of Catalyst Pharmaceuticals stock traded down $0.63 during trading hours on Friday, hitting $22.56. The company had a trading volume of 1,051,439 shares, compared to its average volume of 1,378,861. The company's 50-day moving average is $21.98 and its two-hundred day moving average is $20.72. The company has a market cap of $2.69 billion, a P/E ratio of 19.12, a price-to-earnings-growth ratio of 2.39 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a twelve month low of $13.12 and a twelve month high of $24.64.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Steve Miller sold 50,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the sale, the insider now owns 686,996 shares in the company, valued at $15,065,822.28. This represents a 6.78 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gary Ingenito sold 12,000 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the transaction, the insider now owns 51,391 shares in the company, valued at approximately $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock valued at $1,754,140 over the last ninety days. Insiders own 11.00% of the company's stock.

Analyst Ratings Changes

A number of research firms have issued reports on CPRX. HC Wainwright increased their price target on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a "buy" rating in a research report on Friday, January 10th. Bank of America restated a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Truist Financial lifted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research note on Monday, November 11th. StockNews.com downgraded shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, January 11th. Finally, Stephens started coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an "overweight" rating and a $35.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $32.86.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.